Endoxan

Phase 1Small molecule

CCelyad Oncology SA

Endoxan is one of 124 small molecule programs targeting Lupus Nephritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lupus NephritisActive, not recruiting

Myelodysplastic SyndromeRecruiting

Multiple MyelomaActive, not recruiting

Lupus NephritisPreclinical

Active, not recruiting

Myelodysplastic SyndromePhase 1

Recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

47 2

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

42 3

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

29 4

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

23 5

Elranatamab

Pfizer

Phase 3

27 6

Vepesid

AAvyxa

Phase 3

17 7

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

10 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 9

Adriamycin

HHRYZ Biotech Co.

Phase 3

4 10

Cevostamab

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2035

Phase 1Recruiting

Myelodysplastic Syndrome

NCT04167696

Q1 2037

Phase 1Active, not recruiting

Multiple Myeloma

NCT04613557

Clinical

Trials by Indication[1]

Breast Cancer1 trial

Caelyx Adjuvant in Elderly Breast Cancer

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT00284336·16 enrolled

Lupus Nephritis1 trial

A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy in Lupus Nephritis Patients in Egypt

Completed·NNada Magdy Mansour··NCT05195086·122 enrolled

Myelodysplastic Syndrome1 trial

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Recruiting·CCelyad Oncology SA·Phase 1·NCT04167696·27 enrolled

Dexamethasone1 trial

Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT02046915·60 enrolled

Brentuximab Vedotin1 trial

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Unknown status·CCzech Lymphoma Study Group·Phase 2·NCT05006664·33 enrolled

2 more indications

Vasculitis1 trial

Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Unknown status·LLeiden University Medical Center·Phase 3·NCT03942887·100 enrolled

Multiple Myeloma1 trial

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting·CCelyad Oncology SA·Phase 1·NCT04613557·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Endoxan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Endoxan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Endoxan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celyad Oncology SA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCelyad Oncology SA

Endoxan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2035

Q1 2037

Trials by Indication[1]

Breast Cancer1 trial

Lupus Nephritis1 trial

Myelodysplastic Syndrome1 trial

Dexamethasone1 trial

Brentuximab Vedotin1 trial

Vasculitis1 trial

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News